| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-507
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39541 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2019-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2ba9e993e43a6703fea1a46856c52b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d164e61ed75371623e0037e6ef4d9f8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b45ab5c75050d66b76f306d46989f0cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a5c257f029077f692730e7fdc02006f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a8de9b51ea00ba61d5e4ac77afbd11d |
| publicationDate |
2020-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020015915-A2 |
| titleOfInvention |
USES OF AN ANTI-PD-1 ANTIBODY AND ANTI-CTLA4 ANTIBODY OR ANTIGEN BINDING FRAGMENTS OF THE SAME AS WELL AS A KIT FOR TREATING A PATIENT WITH CANCER |
| abstract |
The present invention relates to methods for treating cancer in a patient which comprises administering an anti-PD-1 antibody or antigen-binding fragment thereof in specific amounts to the patient about every six weeks, in combination with the administration of a anti-CTLA4 antibody to the patient about every six weeks. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen-binding fragment thereof. Compositions are also provided that comprise a dosage of an anti-PD-1 antibody, or antigen binding fragment thereof, and a dosage of an anti-CTLA4 antibody or antigen binding fragment thereof, and uses thereof to treat cancer. |
| priorityDate |
2018-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |